Celastrol inhibits mouse B16-F10 melanoma cell survival by regulating the PI3K/AKT/mTOR signaling pathway and repressing HIF-1α expression

• Published in: Discover. Oncology Vol. 15; no. 1; pp. 178 - 14
• Main Authors: Zhao, Ping, He, Xing-Bo, Chen, Xin-Yue, Li, Zhang-Long, Xing, Wen-Jia, Liu, Wei, Ren, Cong, Han, Xu-Dong, Guo, Bin
• Format: Journal Article
• Language: English
• Published: New York Springer US 21.05.2024; Springer Nature B.V; Springer
• Subjects: Antibodies; Apoptosis; B16-F10; Breast cancer; Cancer Research; Cancer therapies; Celastrol; Cell cycle; Cell growth; Chemotherapy; HIF-α; Hypoxia; Immunotherapy; Internal Medicine; Kinases; Medical prognosis; Medicine; Medicine & Public Health; Melanoma; Metastasis; Molecular Medicine; Natural products; Oncology; PI3K/AKT/mTOR; Radiation; Radiotherapy; Reactive oxygen species; ROS; Skin cancer; Surgical Oncology; Traditional Chinese medicine; Tumors; United States > US; China; B16-F10; HIF-α; PI3K/AKT/mTOR; Celastrol; ROS

Objective Melanoma, with its high degree of malignancy, stands as one of the most dangerous skin cancers and remains the primary cause of death from skin cancer. With studies demonstrating the potential of traditional Chinese medicine to intervene and treat melanoma, we turned our attention to celas...